Brief: Maia Biotechnology Receives FDA’S Fast Track Designation For Ateganosine As A Treatment For Non-Small Cell Lung Cancer
28/07/2025 13:26
July 28 (Reuters) - Maia Biotechnology Inc MAIA.A: MAIA BIOTECHNOLOGY RECEIVES FDA’S FAST TRACK DESIGNATION FOR ATEGANOSINE AS A TREATMENT FOR NON-SMALL CELL LUNG CANCER Source text: ID:nBw2jsqxBa Further company coverage: MAIA.A (Reporting by Anshi Sancheti) ((Anshi.Sancheti@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale